Veralto Corp Ordinary Shares VLTO 深 滬
已收盤 07-18 16:00:00 美东时间
103.34
+0.360
+0.35%
華盛通- 最 高103.57
- 今 開102.85
- 成交量 186.39万股
- 最 低 102.315
- 昨 收 102.98
- 總市值 256.28亿
- 52周最高 114.67
- 市盈率 靜 30.97
- 換手率 0.75%
- 52周最低 83.755
- 委 比 95.56%
- 總股本 2.48亿
- 歷史最高 114.67
- 量 比 1.91
- 振 幅 1.22%
- 歷史最低 64.82
- 每 手 1
- 風險率 5.73%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Veralto Corporation Updates Governance Structure
Veralto Corporation ( ($VLTO) ) has issued an announcement. Veralto Corporation...
05-16 05:20
美股大行评级 | 潜在涨幅195.08%！Absci获Keybanc升目标价至9美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1119548656129204224.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Keybanc：维持Absci(ABSI)"超配"评级，目标价从5美元升至9美元</p> <p>• Keybanc：维持AbCellera Biologics(ABCL)"超配"评级，目标价从4美元升至5美元</p> <
04-17 08:46
What Analysts Are Saying About Veralto Stock
Throughout the last three months, 5 analysts have evaluated Veralto (NYSE:VLTO)...
04-17 05:01
美股大行评级 | 潜在涨幅684.71%！Verve Therapeutics获Canaccord Genuity升目标价至39美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1119185980869894144.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Canaccord Genuity：维持Verve Therapeutics(VERV)"买入"评级，目标价从32美元升至39美元</p> <p>• HC Wainwright & Co.：维持Verve Ther
04-16 09:45
美股大行评级 | 潜在涨幅506.8%！HC Wainwright & Co.上调Verve Therapeutics目标价至25美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1118823510909566976.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Verve Therapeutics(VERV)"买入"评级，目标价从15美元升至25美元</p> <p>• Piper Sandler：维持LENZ Therapeut
04-15 11:35
Citigroup Maintains Neutral on Veralto, Lowers Price Target to $100
Citigroup analyst Andrew Kaplowitz maintains Veralto (NYSE:VLTO) with a Neutral and lowers the price target from $116 to $100.
04-15 05:07
U.S. equity sentiment turns lower in possible bullish signal: Goldman Sachs
A sharp decline in investor sentiment, contrasting global equity performance, and evolving ownership trends are raising key questions about the future of U.S. stock markets, David Kostin, chief U.S. e...
03-23 21:09
Is Veralto Gaining or Losing Market Support?
Veralto's (NYSE:VLTO) short percent of float has fallen 8.6% since its last rep...
03-20 02:45
Veralto declares $0.11 dividend
Veralto (NYSE:VLTO) declares $0.11/share quarterly dividend, in line with previous. Forward yield 0.44% Payable April 30; for shareholders of record March 31; ex-div March 31. See VLTO Dividend Scorec...
03-05 21:21
Veralto Announces Quarterly Dividend
WALTHAM, Mass., March 5, 2025 /PRNewswire/ -- Veralto (NYSE: VLTO), a global leader in essential water and product quality solutions dedicated to Safeguarding the World's Most Vital Resource...
03-05 21:00
